Yueju pill with standard chemotherapy for advanced bile duct cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether adding a Chinese herbal medicine called Yueju pill to standard chemotherapy helps people with advanced bile duct cancer who also have mild anxiety or depression. It aims to see if it can improve mood and possibly help with cancer control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and your doctor expects you to live at least 3 more months.
- You are able to be up and about (ECOG score 0-1).
- Your liver function is good (Child-Pugh class A).
- You have advanced bile duct cancer (including inside or outside the liver or gallbladder).
- You have at least one tumor that can be measured on scans.
- You are about to start or are already receiving chemotherapy as your first or second treatment.
- You have mild to moderate symptoms of anxiety or depression (such as feeling worried or down).
- Your blood counts, liver and kidney function are within acceptable ranges.
- You are not pregnant or breastfeeding and are willing to use contraception if needed.
- You are willing to take a Chinese herbal medicine called Yueju pill along with your usual chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of freezing the tumor (cryoablation), an investigational immunotherapy (QL1706), and a targeted therapy pill (lenvatinib) for people with advanced bile duct cancer that has progressed after initial treatment. The goal is to see if this new combination can help control the cancer and improve outcomes.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This Phase 2 trial tests a combination of three medicines (GEMOX, donafenib, and tislelizumab) for advanced bile duct cancer. It aims to see if the treatment can shrink tumors and improve outcomes in people with certain tumor stage and health test results.
This trial tests a combination of two oral chemotherapy medicines (D07001 softgel plus Xeloda/TS-1) in people with advanced bile duct tract cancer that can’t be removed by surgery. It’s for situations where first-line gemcitabine plus cisplatin chemotherapy no longer worked.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.